AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

3.4M

Current Price

$0.09
-0.0032 (-3.40%)

Book Price

$-0.26
Overvalued by 385.08%
Financial Institution

Company Metrics

  • 1.15 P/E
  • 83.91 P/S
  • 0.68 P/B
  • 0.082 EPS
  • 0.00 / N/A % Dividend
  • 199,700.00 Avg. Vol.
  • 37.44M Shares
  • 3.4M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

affymax inc (AFFY:OTC US)
Businessweek - Jul 13, 2012
Pomerantz law firm announced summary notice of pendency and proposed settlement of Affymax, Inc. class action and settlement hearing.
Affymax Rises on Deal With Fresenius for Kidney Therapy - Bloomberg
Technical Insights on Affymax, Inc. (OTCMKTS: AFFY)
MicroCap Daily - Nov 3, 2014
Affymax, Inc. (OTCMKTS: AFFY) has been moving in a bearish trend since July, 2014 trading around $0.10 per share, but the stock did saw a major bullish rally in the months of January to April , 2014 when its touched its high of $1.04 at a trading ...
Affymax, Inc. (AFFY): Affymax Likely Worthless: Omontys Kills At Least 9x More ...
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax, Inc. (AFFY): Affymax: Emerging Data Supports Conclusion Omontys ...
Seeking Alpha - Nov 12, 2013
The FDA data, combined with the lack of commentary about Omontys on Fresenius' (NYSE:FMS) or Takeda's (OTCPK:TKPHF) latest earnings calls and the cash burn at Affymax (OTCQB:AFFY), all lead us to believe that the end is near for Affymax.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
Affymax, Inc. (AFFY): Affymax: Putting The Pieces Together [Amgen, Inc ...
Seeking Alpha - Aug 24, 2013
Affymax's sole drug product is OMONTYS® (peginesatide) Injection ("OMONTYS"), which was approved by the FDA in 2012 and well received by the medical community as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on ...
The end for Affymax (AFFY)
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
Affymax, Inc. (AFFY): Don't Believe In Affymax - The Stock Is Probably Worthless
Seeking Alpha - Aug 29, 2013
Investors in Affymax (OTCQB:AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the ...
Affymax Is Still Alive
Seeking Alpha - May 28, 2013
Following up on a previous article in which I wrote about a possible reversal, you will see that biotech company Affymax (OTCQB:AFFY) stock did in fact bounce in share price recently.
Hard Times for Affymax, Inc. (OTCMKTS:AFFY)
HotStocked - Aug 7, 2013
We have been keeping an eye on Affymax, Inc. (OTCMKTS:AFFY, AFFY message board) and their dramatic story of a NASDAQ listed company that went on to trade in the OTC Markets after it did the right thing.